Scarica l'app Stockscreener
120.94
0.17%
0.20
Dopo l'orario di chiusura:
121.00
0.06
+0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$120.74
Aprire:
$120.415
Volume 24 ore:
5.40M
Relative Volume:
0.80
Capitalizzazione di mercato:
$150.06B
Reddito:
$28.80B
Utile/perdita netta:
$6.31B
Rapporto P/E:
24.06
EPS:
5.0273
Flusso di cassa netto:
$9.37B
1 W Prestazione:
-1.52%
1M Prestazione:
+6.40%
6M Prestazione:
+13.93%
1 anno Prestazione:
+36.22%
Intervallo 1D:
$118.70
$121.14
Intervallo di 1 settimana:
$118.70
$124.61
Portata 52W:
$86.08
$124.61
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Confronta GILD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
120.94 | 149.82B | 28.80B | 6.31B | 9.37B | 5.0273 |
|
LLY
Lilly Eli Co
|
825.45 | 736.03B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.40 | 463.72B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.99 | 403.22B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.36 | 254.84B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.49 | 217.76B | 63.43B | 16.42B | 14.72B | 6.4861 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Is Gilead Sciences Inc. (GIS) stock inflation resilientEarnings Beat & Accurate Entry and Exit Point Alerts - newser.com
Is Gilead Sciences Inc. stock cheap at current valuation2025 Valuation Update & Precise Buy Zone Identification - newser.com
Will Gilead Sciences Inc. stock remain a Wall Street favorite2025 Support & Resistance & Free Technical Pattern Based Buy Signals - newser.com
What To Expect From Gilead In Q3 2025 (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences patents new PI3Kα inhibitors - BioWorld MedTech
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - BioSpace
Precision Trading with Gilead Sciences Inc. (GILD) Risk Zones - news.stocktradersdaily.com
TD Cowen Raises Price Target for Gilead Sciences (GILD) to $125 | GILD Stock News - GuruFocus
Commentary: A breakthrough to prevent HIV shouldn’t break the bank - The Boston Globe
Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value - Yahoo Finance
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Wolfe Research Adjusts Gilead Sciences Price Target to $140 From $135, Maintains Outperform Rating - MarketScreener
TD Cowen Adjusts Gilead Sciences Price Target to $125 From $115, Maintains Buy Rating - MarketScreener
Gilead to present new data on Livdelzi for PBC at Liver Meeting 2025 - Investing.com
Gilead to present liver disease data at AASLD conference - StreetInsider
(Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - Business Wire
Using economic indicators to assess Gilead Sciences Inc. potentialJuly 2025 Trade Ideas & Smart Money Movement Alerts - newser.com
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
CVS (CVS) Delays Adding Gilead's Yeztugo Over Pricing Concerns - GuruFocus
Gilead Sciences (GILD) Halts Phase 1 HIV Treatment Trial - GuruFocus
Gilead discontinues early-stage trial for long-acting injectable for HIV - Seeking Alpha
Gilead Sciences stock rating reiterated by RBC amid HIV drug setback - Investing.com
Gilead Sciences (GILD) Halts Phase 1 Study for HIV Treatment - GuruFocus
CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies - statnews.com
What to Expect From Gilead Sciences' Next Quarterly Earnings Report - Yahoo Finance
Exit strategy if you’re trapped in Gilead Sciences Inc.Quarterly Investment Review & Low Risk Investment Opportunities - newser.com
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia - GlobeNewswire Inc.
How to build a dashboard for Gilead Sciences Inc. stockJuly 2025 Pullbacks & Verified Momentum Stock Watchlist - newser.com
Health Canada conditionally approves Gilead Sciences’ Lyvdelzi for PBC - Pharmaceutical Technology
Is Gilead Sciences Inc. (Common Stock) (GIS0) stock a momentum leaderEarnings Recap Report & Entry Point Confirmation Alerts - newser.com
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock enhance shareholder value2025 Risk Factors & Reliable Breakout Forecasts - newser.com
Will Gilead Sciences Inc. outperform the marketDividend Hike & Daily Volume Surge Trade Alerts - newser.com
Why Gilead Sciences Inc. (Common Stock) (GIS0) stock attracts wealthy investorsEarnings Beat & Free Weekly Watchlist of Top Performers - newser.com
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock boost dividends furtherMarket Trend Report & Capital Protection Trade Alerts - newser.com
Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs - statnews.com
100 Organizations Denounce Gilead on Price Hikes Gutting ADAP - AIDS Healthcare Foundation
LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - BioSpace
LYVDELZI® RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - Investing News Network
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP - Yahoo Finance
What makes Gilead Sciences Inc. (Common Stock) (GIS0) stock appealing to growth investorsWeekly Loss Report & Weekly Watchlist of Top Performers - newser.com
Targets Report: Will Gilead Sciences Inc. (GIS) stock extend growth storyJuly 2025 Chart Watch & Safe Entry Point Alerts - nchmf.gov.vn
Is Gilead Sciences Inc. stock bottoming outTrade Analysis Summary & AI Enhanced Market Trend Forecasts - newser.com
Gilead Sciences (GILD): Assessing Valuation After Major Trodelvy Breast Cancer Breakthrough and HIV Advances - simplywall.st
Gilead to spotlight new virology data across HIV, viral hepatitis and respiratory diseases at IDWeek 2025 - European AIDS Treatment Group
How Gilead Sciences Inc. (Common Stock) (GIS0) stock trades after rate cutsEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com
Will Gilead Sciences Inc. stock keep outperforming rivalsMarket Growth Summary & Breakout Confirmation Alerts - newser.com
Can Gilead Sciences Inc. hit a new high this monthQuarterly Trade Review & Short-Term High Return Strategies - newser.com
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock announce a stock splitAnalyst Downgrade & Smart Allocation Stock Tips - newser.com
Will Gilead Sciences Inc. (GIS) stock deliver compounding returnsQuarterly Risk Review & Verified Swing Trading Watchlists - nchmf.gov.vn
Fed Watch: Is Gilead Sciences Inc. (GIS) stock inflation resilientJuly 2025 Earnings & Low Volatility Stock Recommendations - nchmf.gov.vn
Aug Shorts: Will Gilead Sciences Inc. (Common Stock) (GIS0) stock announce a stock splitJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - nchmf.gov.vn
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):